Researchers conducted a systematic review of eight studies that reported data to calculate prognostic accuracy of surface screening among neonates for predicting late-onset sepsis. They assessed the risk of bias and performed a meta-analysis. The studies were performed in six countries in Europe, Asia and North America and included 4,829 participants.
The study shows all studies were at high risk of bias. Body surface screening to predict late-onset sepsis showed a pooled sensitivity of 41 percent and pooled specificity of 56 percent.
“Carefully planned and conducted prospective studies, including randomized trials, are needed to clarify the potential value of this measure for the prediction and prevention of late-onset sepsis,” study authors concluded.
More articles on healthcare quality:
Physicians don’t see the financial distress of cancer treatments, study finds
New hospital certification offered for heart failure treatment
How a Lean-based QI program increased discharges by noon
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
